Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.

Patel TB, Pequignot E, Parker SH, Leavitt MC, Greenberg HE, Kraft WK.

Int J Clin Pharmacol Ther. 2007 Mar;45(3):161-8.

PMID:
17416111
2.

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.

García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group.

BMC Pharmacol. 2010 Nov 23;10:15. doi: 10.1186/1471-2210-10-15.

3.

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.

García-Vega Y, García-García I, Collazo-Caballero SE, Santely-Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, Alfonso-Alvarado C, Cabrera-Placeres M, Castro-Basart N, Duncan-Roberts Y, Carballo-Treto TI, Soto-Matos J, Izquierdo-Toledo Y, Vázquez-Blomquist D, García-Iglesias E, Bello-Rivero I.

BMC Pharmacol Toxicol. 2012 Dec 28;13:20. doi: 10.1186/2050-6511-13-20.

4.
5.

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S.

Clin Pharmacol Ther. 2000 Nov;68(5):556-67.

PMID:
11103758
6.

Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.

De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG.

J Interferon Cytokine Res. 2008 Feb;28(2):113-22. doi: 10.1089/jir.2007.0073.

PMID:
18279106
7.

A phase I study of recombinant interferon-beta in patients with advanced malignant disease.

Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M.

Clin Cancer Res. 1999 Dec;5(12):3990-8.

8.

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM.

Br J Clin Pharmacol. 1998 Dec;46(6):563-70.

9.

Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.

Jeon S, Juhn JH, Han S, Lee J, Hong T, Paek J, Yim DS.

J Transl Med. 2013 Oct 2;11:240. doi: 10.1186/1479-5876-11-240.

10.

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.

Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC.

J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8.

PMID:
2472488
12.

Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.

Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducongé J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P.

Drugs R D. 2004;5(5):271-80.

PMID:
15357626
13.

Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.

Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M.

J Clin Pharmacol. 2002 Oct;42(10):1109-15.

PMID:
12362925
14.

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

Stürzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B.

J Interferon Cytokine Res. 1999 Nov;19(11):1257-64.

PMID:
10574618
15.

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.

Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C.

J Pharmacol Exp Ther. 2002 Nov;303(2):540-8.

17.

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.

García-García I, Hernández-González I, Díaz-Machado A, González-Delgado CA, Pérez-Rodríguez S, García-Vega Y, Campos-Mojena R, Tuero-Iglesias ÁD, Valenzuela-Silva CM, Cruz-Ramírez A, Martín-Trujillo A, Santana-Milián H, López-Saura PA, Bello-Rivero I; CIGB-128-A Study Group.

BMC Pharmacol Toxicol. 2016 Dec 7;17(1):58.

18.

Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.

Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Garcia A, Moore PA, Yu R, Subramanian GM.

Antivir Ther. 2006;11(7):901-8.

PMID:
17302252
19.

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.

Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J.

J Neuroimmunol. 1999 Sep 1;99(1):131-41.

PMID:
10496186
20.

Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.

Liberati AM, Garofani P, De Angelis V, Di Clemente F, Horisberger M, Cecchini M, Betti AR, Palmisano L, Astolfi S, Nastari A, et al.

J Interferon Res. 1994 Apr;14(2):61-9.

PMID:
8077767

Supplemental Content

Support Center